BioCryst Taps Alnylam Exec to Lead R&D Amid Pipeline Expansion
Event summary
- BioCryst appoints Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer effective April 6, 2026.
- Menon previously served as Chief Development Officer at Alnylam Pharmaceuticals, leading the approval of AMVUTTRA® (vutrisiran).
- BioCryst is advancing the navenibart program toward a potential Biologics License Application (BLA).
- Menon brings experience from Pfizer, where he co-led the development of PAXLOVID™.
The big picture
BioCryst’s appointment of Menon underscores its focus on disciplined drug development and regulatory success amid a strategic shift toward expanding its rare disease portfolio. The move follows the acquisition of Astria Therapeutics and the navenibart program, signaling a push for repeated launches in the rare disease space. Menon’s track record at Alnylam and Pfizer suggests a focus on scaling global R&D and improving success rates, aligning with BioCryst’s long-term value creation goals.
What we're watching
- Pipeline Execution
- How Menon’s leadership will impact the pace of navenibart’s BLA submission and other pipeline programs.
- Capital Allocation
- Whether BioCryst can balance risk and reward in its growing rare disease portfolio.
- Regulatory Delivery
- The likelihood of flawless regulatory execution for BioCryst’s innovative therapies under Menon’s guidance.
Related topics